Information Provided By:
Fly News Breaks for June 18, 2018
CYTK
Jun 18, 2018 | 05:27 EDT
Piper Jaffray analyst Edward Tenthoff lowered his price target for Cytokinetics to $13 after the company this weekend reported Phase II data on reldesemtiv in spinal muscular atrophy. The analyst believes reldesemtiv was well-tolerated and could be dosed higher. Tenthoff keeps an Overweight rating on Cytokinetics after taking over coverage of the name.
News For CYTK From the Last 2 Days
There are no results for your query CYTK